During Monday’s Current trade, Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), gain 1.41% to $136.93.
Vertex Pharmaceuticals Incorporated ( VRTX) stated merged financial results for the quarter ended June 30, 2015. Vertex also raised its financial guidance for total 2015 KALYDECO® (ivacaftor) revenues and reiterated its preceding guidance for non-GAAP operating expenses.
Second Quarter 2015 Non-GAAP Financial Results
The non-GAAP financial results for the second quarter 2015 and second quarter 2014 exclude stock-based compensation expense, costs related to the relocation of the company’s corporate headquarters, hepatitis C-related revenues and costs and other adjustments.
Total Non-GAAP Revenues: Total non-GAAP revenues for the second quarter of 2015 were $159.9 million, counting $154.9 million in net product revenues from KALYDECO and $5.0 million from royalty revenues.
- Net Product Revenues from KALYDECO: Vertex’s second quarter 2015 net product revenues from KALYDECO were $154.9 million contrast to $113.1 million for the second quarter of 2014. The raised KALYDECO net product revenues, contrast to the second quarter of 2014, resulted primarily from additional people being treated with KALYDECO in both U.S. and ex-U.S. markets.
Non-GAAP Cost of Product Revenues and Royalty Expenses (COR): Total combined non-GAAP COR expenses for the second quarter of 2015 were $16.5 million, contrast to $11.1 million for the second quarter of 2014.
Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF); and advancing its research and early-stage development programs.
Shares of Synthetic Biologics Inc (NYSEMKT:SYN), inclined 0.31% to $3.19, during its current trading session.
Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, intends to release its financial results for the three and six months ended June 30, 2015 on Monday, August 10, 2015, and to host a conference call the same day at 8:30 a.m. EDT.
Synthetics Biologics, Inc., a clinical-stage biotechnology company, develops pathogen-specific therapies for serious infections and diseases with a focus on protecting the microbiome. It is developing an oral biologic to protect the gut microbiome (gastrointestinal (GI) microflora) from intravenous (IV) antibiotics for the prevention of C. difficile infection; an oral statin treatment to reduce the impact of methane producing organisms on irritable bowel syndrome with constipation (IBS-C); and a monoclonal antibody combination for the treatment of Pertussis.
International Game Technology Ordinary Shares (NYSE:IGT), during its Monday’s current trading session decreased -0.96% to $19.61.
International Game Technology PLC (IGT) Gold and Dragon™ slots created good fortune for one lucky player who won a $1,069,443 jackpot at Valley View Casino & Hotel in San Diego, Calif., on July 17, 2015.
The new millionaire, Radenka D., said that she was in complete shock after winning the jackpot, and added that Valley View Casino is her favorite casino and IGT’s Gold and Dragon is her favorite slot machine.
International Game Technology PLC operates and provides a range of services and technology products across lotteries, machine gaming, sports betting, and interactive gaming markets in North America, Asia, and Europe. It provides online lottery transaction processing systems; a suite of lottery-enabled point-of-sale terminals; supplies instant ticket games; and provides printing services, instant ticket marketing plans, graphic design, programming, production, packaging, and shipping and delivery services.
Finally, Credit Suisse Group AG (ADR) (NYSE:CS), gained 0.65%, to $29.64.
Credit Suisse NASDAQ Gold FLOWS 103 Index and the Credit Suisse NASDAQ Silver FLOWS 106 Index concluded the notional sale of options on GLD shares and SLV shares with August expiration. We expect that the notional cash distribution generated by this sale of options will be withdrawn from the Indices on August 17, 2015, subject to adjustment in the event of any market disruption events.
Assuming no redemption or acceleration of the ETNs and that the notional cash distribution is withdrawn from the Indices on August 17, 2015, we expect to declare a coupon of $0.0469 per ETN on the GLDI ETNs and a coupon of $0.0857 per ETN on the SLVO ETNs for payment on or around August 25, 2015, payable to the holder of record on August 20, 2015. The predictable coupon amount may be subject to change upon the occurrence of a disruption event or other unforeseen circumstances.
Credit Suisse Group AG, together with its auxiliaries, provides various financial services to private, corporate, institutional, government clients, and high-net-worth individuals, in addition to affluent and retail clients worldwide. The company operates through two segments, Private Banking & Wealth Administration and Investment Banking.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
